Intracellular mechanisms can induce migraine attacks independent of CGRP receptor activation
nausea, migraine-associated, phonophobia, migraine, Migraine, photophobia
MIGRAINE, MIGRAINE
We demonstrated that erenumab can alleviate migraine attack induction with CGRP with 10 of 37 [27% (95% CI, 13–41)] participants developing migraine attacks compared to 20 out of 38 [53% (95% CI, 37–69)] participants who received placebo (
Migraine attack induction rateCalcitonin gene-related peptide (CGRP): There was a significant difference in the incidence of migraine attacks following administration of CGRP in individuals with migraine randomized to erenumab compared to placebo (We found no difference in cilostazol-induced migraine attacks between participants who received erenumab versus placebo. Cilostazol-induced migraine attacks in 28 of 37 [76% (95% CI, 62–90)] participants in the erenumab group compared to 31 out of 38 [82% (95% CI, 69–94)] participants in the placebo group (
The incidence of migraine-associated symptoms in the active-treatment group compared to the placebo-treatment group was, for nausea, 17 (46%) and 22 (58%), photophobia, 24 (65%) and 23 (61%), and phonophobia, 17 (46%) and 19 (50%), respectively. The median time to onset in the active-treatment group compared to the placebo-treatment group was, for nausea, 240 min (range, 10–660 min) and 300 min (range, 10–660 min), photophobia, 310 min (range, 10–420 min) and 240 min (range, 10–540 min), and phonophobia, 180 min (range, 10–420 min) and 240 min (range, 20–540 min), respectively; the median time of duration in the active-treatment group compared to the placebo-treatment group was, for nausea, 210 min (range, 60–540 min) and 150 min (range, 30–340 min), photophobia, 300 min (range, 50–710 min) and 420 min (range, 30–710 min), and phonophobia, 315 min (range, 30–640 min) and 240 min (range, 50–600 min), respectively.